Skip to main content
. 2018 Jun 21;9:664. doi: 10.3389/fphar.2018.00664

FIGURE 6.

FIGURE 6

Trimebutine inhibits tumor growth in a U-87 MG glioblastoma xenograft model. (A) Representative photographs of the gross U-87MG xenograft glioblastoms from nude mice treated with trimebutine or vehicle control. (B) The tumor volume was evaluated before and after vehicle control/trimebutine treatment. Tumor weight was measured after dissection (∗P < 0.05 vs. vehicle control group). (C) The average final tumor weight in trimebutine-treated mice was significantly lower than that in DMSO-treated nude mice (∗∗P < 0.01 vs. vehicle control group). (D) Representative images for H&E staining from either group was shown. (E) Representative images for TUNEL-positive and PI-positive cells in the tumor tissue. TUNEL (green) and PI (red). Scale bar, 200 μm. (F) At the end of the experiment, tumor tissues were excised from mice, and the protein lysates extracted from the tumor tissues were assessed by western blot for p-AKT, AKT, p-ERK, ERK, Bcl-2, Bax, and GAPDH, respectively.